SIOC 中文
CJOG
Adv search

Chinese Journal of Organic Chemistry >

2012 , Vol. 32 >Issue 10: 1894 - 1898

DOI: https://doi.org/10.6023/cjoc201203001

Articles

Modify a Fragment of Arctigenin with Pyrimidine Derivatives

  • Wang Huanhuan ,
  • Wu Ping ,
  • Kang Hong ,
  • Xu Liang ,
  • Zhu Ruixin ,
  • Kang Tingguo
Expand
  • a School of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian 116600;
    b School of Life Sciences and Technology, Tongji University, Shanghai 200092

Received date: 2012-03-19

  Revised date: 2012-05-29

  Online published: 2012-10-27

Supported by

Project supported by the National Natural Science Foundation of China (No. 30976611), the Research Fund for the Doctoral Program of Higher Education of China (No. 20100072120050) and the Traditional Chinese Medicine Modernization of Shanghai (No. 09dZ1972800).

Fold

Abstract

In order to enhance the anti-tumor activity of the arctigenin and reduce the side effects of pyrimidine, arctigenin was modified with pyrimidine derivatives having biological activities. In this research, some halogenated pyrimidines were linked to the phenolic hydroxyl group of the arctigenin to gain eleven new compounds, and the structures of them were identified by LC-MS and 1H NMR. So, the number of the anti-tumor compound libraries of compounds based on arctigenin was increased, and these compounds were prepared for the in-vitro activity screening in the near future. By our work, when enhance the alkalinity and increase the water content in DMF, the etherification reaction is promoted, to a certain extent.

Key words： arctigenin; structural modification; pyrimidine derivatives; nonidentical twin drug

Cite this article

Wang Huanhuan , Wu Ping , Kang Hong , Xu Liang , Zhu Ruixin , Kang Tingguo . Modify a Fragment of Arctigenin with Pyrimidine Derivatives[J]. Chinese Journal of Organic Chemistry, 2012 , 32(10) : 1894 -1898 . DOI: 10.6023/cjoc201203001

References

[1] Fu, L.-C; Xu, P.-P; Liu, N; Yang, Z.-F.; Zhang, F.-X.; Hu, Y.-J. Trad. Chin. Drug Res. Clin. Pharmacol. 2008, 4, 266 (in Chinese). (符林春, 徐培平, 刘妮, 杨子峰, 张奉学, 胡英杰, 中药新药与临床药理, 2008, 4, 266.)



(b) Fischer, J.; Reynolds, A.-J.; Sharp, L.-A. Org. Lett. 2004, 6, 1345.



(c) Mi, J.-Y.; Song, C.-Q. Lishizhen Medicine Materia Medica Res. 2002, 13, 168 (in Chinese).



(米靖宇, 宋纯清, 时珍国医国药, 2002, 13, 168.)



(d) Wang, L.; Zhao, F.; Liu, K. Chin. Trad. Herb. Drugs 2008, 39, 467 (in Chinese).



(王潞, 赵烽, 刘珂, 中草药, 2008, 39, 467.)



[2] (a) Stephen, W.-W.; Hallstrom, K.-N. J. Org. Chem. 2006, 71, 1080.



(b) Colombo, M.; Giglio, M.; Peretto, I. J. Heterocycl. Chem. 2008, 45, 1077.



[3] Tibiletti, F.; Simonetti, M.; Nicholas, K.-M.; Palmisano, G.; Parravicini, M.; Imbesi, F.; Tollari, S.; Penoni, A. Tetrahedron 2010, 66, 1280.



[4] Shi, J.; Manolikakes, G.; Yeh, C. J. Am. Chem. Soc. 2011, 133, 8014.

Options
Outlines

/

〈 〉